Role of age-associated TET2 mutations in atherosclerosis
Description: The accumulation of somatic DNA mutations over time is a hallmark of aging in many tissues. However, the causal role of somatic mutations in age-associated disorders other than cancer is a matter of debate, and remains unexplored in the setting of cardiovascular disease (CVD), the leading cause of death in elderly individuals. Recent large exome sequencing studies in humans have shown that aging is associated with an increased frequency of somatic mutations in the hematopoietic system, which provide a competitive growth advantage to the mutant cell and allow its clonal expansion (clonal hematopoiesis). Unexpectedly, these somatic mutations were associated with a higher rate of CVD-related deaths, as well as higher incidence of coronary artery disease and stroke, suggesting a previously unrecognized link between somatic mutations in bone marrow-derived cells and atherosclerotic CVD. However, whether there is a causal connection between these somatic mutations and CVD remains unclear and the potential underlying mechanisms are completely unknown. One of the most frequently mutated genes in these studies was TET2, an epigenetic regulator that has been suggested to play important roles in the modulation of immune cell function. However, its potential role in CVD and atherosclerosis development remains largely unexplored. The proposed project aims to test the hypothesis that clonal expansion of TET2-deficient hematopoietic cells contributes to atherosclerotic plaque development in hypercholesterolemic mice. Collectively, we expect that these studies will provide mouse genetic evidence supporting a causal connection between Tet2 loss-of-function somatic mutations in blood cells and atherosclerotic CVD. Furthermore, they may provide mechanistic insight into the cellular processes affected by these mutations, which could contribute to the design of personalized therapies for individuals carrying mutations in this gene or related epigenetic regulators.
Funder: American Heart Association
Amount: $231,000
Funding type: fellowship
Funder scheme: Scientist Development Grant
Start date: 2017-01-01
End date: 2019-01-28
Investigator: Jose Fuster (lead)
Institution: University of Virginia
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Funded outputs count: 3
Funder award ID: 17SDG33400213
OpenAlex ID: G5848767049
